Key clinical point: Low-dose calcipotriol ointment significantly improved wound healing and itch in people with recessive dystrophic epidermolysis bullosa (RDEB).
Major finding: A greater percentage of wound size reduction was observed after 2 weeks when the ointment was applied (88.4% vs. 65.5% for placebo; P less than .006).
Study details: A phase 2, randomized, double-blind, two-arm, placebo-controlled study of nine adults with RDEB.
Disclosures: The study was funded by DEBRA Austria. The presenting author, Dr. Guttmann-Gruber had no conflicts of interest to disclose.
Guttmann-Gruber C et al. EB World Congress 2020. Poster 34.